Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURI-2 dapagliflozin trial for prevention of postoperative acute kidney injury after elective cardiac surgery
NL-OMON60524Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin in acute kidney failure (AKF), sponsored by Amsterdam University Medical Center. Primary endpoint: Incidence of acute kidney injury within 7 days after surgery. Started Jun 2023; status: completed.
02
Drugs
dapagliflozin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on NL-OMON60524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60524.